Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Personalized treatment approaches in epilepsy

Bernhard Steinhoff, MD, PhD, Kork Epilepsy Center, Kehl-Kork, Germany, discusses the progress being made in introducing personalized treatment approaches for epilepsy management. Prof. Steinhoff highlights tuberous sclerosis complex (TSC) and Dravet syndrome as areas leading the field. Everolimus has been introduced to treat TSC-associated seizures which, unlike most epilepsy treatments, addresses the underlying pathophysiology of the condition. In Dravet syndrome, approaches that target the causative SCN1A gene mutation are under investigation. This interview took place during the European Academy of Neurology 2021 congress.


Prof. Steinhoff reports the following disclosures:
Paid consultant/advisor/lecturer: Arvelle, B. Braun Melsungen, Desitin, Eisai, GW Pharmaceuticals, Neuraxpharm, UCB and Zogenix
Research support: Eisai, GW Pharmaceuticals, Precisis, SK Life Science, UCB, and Zogenix.